Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study

Overview of attention for article published in The Journal of Urology, June 2007

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter: 2 X users

patent: 11 patents

Readers on

mendeley: 54 Mendeley

So far, Altmetric has seen 11 patents that reference this research output.

FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS

Application EP-4454709-A2

European Patent Office

30 Oct 2024

FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS

Application WO-2019213510-A1

World Intellectual Property Organisation (WIPO)

07 Nov 2019

Extracellular matrix materials as vaccine adjuvants for diseases associated with…

Grant US-9308252-B2

United States of America

12 Apr 2016

Metastasis inhibition preparations and methods

Grant US-9283266-B2

United States of America

15 Mar 2016

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 7 additional patents.